Congress mulling whether to move human growth hormone to Schedule III
A nonprofit group concerned over short stature in kids opposes legislation now under consideration in Congress that would move human growth hormone into Schedule III of the Controlled Substances Act.
Should human growth hormone be classified as a Schedule III controlled substance? That's what Congress is set to vote on this week. The House Bill 4911, claiming that they could hurt children's health, such as by affecting their frequency of doctor visits or the cost of copays.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
